Investor Day 2025 TM Transform. Innovate. Accelerate. 2025 INVESTOR DAY 1 Welcome and Opening Remarks Ann Giancristoforo Vice President, Investor Relations 2 2 2025 INVESTOR DAY 2025 INVESTOR DAY Forward looking statements On January 15, 2025, DuPont de Nemours, Inc. ("DuPont", or after the completion of the Intended Electronics Separation, "New DuPont") announced it is targeting November 1, 2025 to complete the intended separation of its Electronics business (the "Intended Electronics Separation") by way o ...

Core Insights - The company has focused on returning to basics, emphasizing accountability, agility, and innovation to improve business performance [1] - Progress has been made in three key priorities: top line growth through innovation and commercial excellence, operational performance, and effective capital deployment [2] Product Innovation - In the first half of the year, the company launched 126 products, which is nearly equivalent to the total of 128 products launched in all of 2023 [2]

Summary of 3M FY Conference Call - September 11, 2025 Company Overview - **Company**: 3M (NYSE: MMM) - **Industry**: Multi-Industry, including Safety and Industrial, Consumer, Electronics, Automotive, and more Key Points and Arguments Leadership and Strategic Focus - The CEO, Bill Brown, emphasized a return to basics, focusing on business fundamentals, culture, accountability, agility, and innovation [3][4] - Three main priorities were outlined: top-line growth through innovation and commercial excellence, operational performance, and effective capital deployment [3][4] Product Launches and Innovation - 3M launched 126 products in the first half of 2025, a significant increase from 128 in all of 2023, representing a 70% year-over-year growth [4][5] - The company is on track for over 215 product launches in 2025, aiming for 1,000 launches over the next three years [4][5] Financial Performance and Growth Metrics - The Safety and Industrial Business Group (SIBG) showed improvement with organic growth of 2.5% in the first half of 2025, up from negative growth in the previous year [5][6] - Margins improved by 250 basis points year-over-year, with a target of 25% margins by 2027 [6][7] - The company aims for a billion dollars of growth above macroeconomic trends over the next three years, with half from commercial excellence and half from new product introductions [18][24] Operational Excellence - The CEO highlighted the importance of operational excellence, including metrics like on-time and in-full (OTIF) delivery, which improved from 80% to 89.6% year-over-year [11][12] - The focus on asset utilization is critical, with current utilization at 59%, aiming to improve surge capacity and reduce excess assets [13][14] Market Conditions and Expectations - The macroeconomic environment remains sluggish, with expectations of low single-digit growth in various sectors, including automotive and consumer markets [31][32] - China remains a strong market for 3M, contributing over 10% of the company's revenue, although growth is expected to soften in the back half of the year [36][38] Portfolio Management and Divestitures - The company is reviewing its portfolio to focus on higher growth and margin potential businesses, with about 10% of the portfolio identified for potential divestiture [25][26] - Priority verticals for investment include semiconductors, data centers, aerospace, and automotive [25][26] Litigation and Financial Management - Ongoing litigation includes public water supplier issues and personal injury cases, with settlements structured to manage cash flow over time [40][41] - The company maintains a strong balance sheet to handle litigation costs and is focused on cash management strategies [44][45] Future Outlook - The CEO expressed confidence in achieving growth targets, with expectations of accelerating growth in the back half of 2025 [23][31] - The company is committed to innovation and improving operational metrics to drive sustainable growth [10][18] Additional Important Insights - The company is phasing out PFAS production by the end of 2025, focusing on alternative materials and innovation [46][47] - The impact of tariffs is being managed, with expectations of offsetting costs through pricing and operational efficiencies [51][52]

Financial Data and Key Metrics Changes - The company reported a Q2 EBITDA that was 19% higher than the same quarter last year, and H1 EBITDA was nearly 20% above H1 last year, marking the fifth consecutive quarter of EBITDA growth [9][10] - Gross margin improved from 26.8% to 29.6%, and EBITDA margin increased from 10.8% to 13.3% compared to the same period last year [11] - Free cash flow increased by $24 million to a total of $32 million, reflecting strong cash management [15][32] Business Line Data and Key Metrics Changes - The company achieved a top-line sales increase for the first time since Q3 2022, reaching $908 million, driven by a 6% volume growth that offset a 3% decline in prices [17] - Gross profit increased by 14%, with a gross margin of 29% in Q2 2025 compared to 26% in Q2 2024 [17][21] - EBITDA for H1 2025 reached $244 million, a 20% increase compared to the previous year [21] Market Data and Key Metrics Changes - Sales in North America grew by approximately 20%, benefiting from a rebound in market volumes [25] - Sales in Europe, Africa, and the Middle East showed a slight drop, but would have grown by 3% if not for geopolitical issues in Turkey [24] - The company faced significant price pressure in Latin America, particularly in Brazil and Argentina, impacting overall performance in that region [28] Company Strategy and Development Direction - The company is focused on a transformation strategy called "Fight Forward," aimed at improving profitability and growing the top line by focusing on high-margin products [12][59] - The management emphasized the importance of operational efficiency and cost reduction initiatives that have contributed to improved margins [12][19] - The company aims to leverage its differentiated product portfolio to gain market share in key regions moving forward [59] Management's Comments on Operating Environment and Future Outlook - Management noted that the agrochemical market remains in an oversupply situation, primarily due to overcapacity from China, which continues to exert price pressure [5][6] - Despite challenges, there are signs of market stabilization, with normalized inventory levels leading to improved volume dynamics [46][48] - The management expressed confidence in the company's ability to navigate the current environment and capitalize on growth opportunities [59][60] Other Important Information - The company has undergone significant restructuring, which has resulted in a narrowing of net profit losses, with reported net profit at $43 million in Q2 2025, down 64% from the previous year [19][22] - The company has a net debt to EBITDA ratio of 2.5, which is within the required covenant limits [34] Q&A Session Summary Question: What are the main challenges faced in the market? - Management highlighted ongoing price pressures due to farmer profitability issues and geopolitical factors affecting sales in certain regions [47][48] Question: How is the company addressing operational efficiency? - The company has implemented various initiatives under the "Fight Forward" plan to reduce costs and improve operational efficiency, contributing to better margins [12][19] Question: What is the outlook for growth in key markets? - Management expressed optimism about growth opportunities in North America and Europe, while acknowledging challenges in Latin America and India [25][28]

Financial Data and Key Metrics Changes - The company reported a Q2 EBITDA of $180 million, which is 19% higher than the same quarter last year, and H1 EBITDA was nearly 20% above H1 last year [9][18] - Gross margin improved from 26.8% to 29.6%, and EBITDA margin increased from 10.8% to 13.3% [11] - Free cash flow increased by $24 million to a total of $32 million [15][30] Business Line Data and Key Metrics Changes - The company achieved a top-line sales increase for the first time since Q3 2022, reaching $906 million, driven by a 6% volume growth that offset a 3% price decline [17] - Gross profit increased by 14%, with a gross margin of 29% in Q2 2025 compared to 26% in Q2 2024 [17][20] Market Data and Key Metrics Changes - Sales in North America grew by approximately 20%, benefiting from a rebound in market volumes [24] - Sales in Europe, Africa, and the Middle East showed a slight drop, but would have grown by 3% if not for geopolitical issues in Turkey [22] - Latin America experienced a drop in sales primarily due to significant price pressure in Brazil and Argentina [26] Company Strategy and Development Direction - The company is focused on a transformation strategy called "Fight Forward," aimed at improving profitability and then growing the top line [13][56] - The management emphasized the importance of focusing on high-margin products and exiting low-profit segments [20][22] Management's Comments on Operating Environment and Future Outlook - Management noted that the agrochemical market remains in an oversupply situation, primarily due to overcapacity from China, which continues to exert price pressure [5][6] - There are signs of market stabilization, with normalized channel inventories and a shift towards more strategic conversations with customers [43][46] Other Important Information - The company has a net debt to EBITDA ratio of 2.5, which is within the required covenant limits [32] - The management highlighted the importance of cash flow management and operational efficiency as key components of their strategy [15][30] Q&A Session Summary Question: What are the main challenges faced in the Turkish market? - The company faced significant sales losses in Turkey due to geopolitical issues and restrictions imposed by the Turkish government [19] Question: How is the company addressing pricing pressures? - Management acknowledged ongoing pricing pressures due to farmer profitability issues and overcapacity in the market, but emphasized their focus on operational efficiencies to mitigate these impacts [6][46]

Financial Data and Key Metrics Changes - The company reported adjusted earnings per share of $2.16, an increase of 12% year-over-year, exceeding expectations [6][20] - Organic sales growth was 1.5%, with all three business groups reporting positive growth for the third consecutive quarter [6][17] - Operating margins increased by 290 basis points year-over-year, driven by productivity and cost controls [6][19] - Free cash flow was solid at $1.3 billion for the quarter, with a conversion rate of 110% [7][21] Business Line Data and Key Metrics Changes - Safety and Industrial organic sales grew by 2.6% in Q2, with six out of seven divisions posting positive results [22] - Transportation and Electronics adjusted sales were up 1% organically, driven by commercial graphics and auto personalization [23] - Consumer business saw a slight increase of 0.3% organically, despite soft consumer sentiment [24] Market Data and Key Metrics Changes - Growth was led by China, which was up mid-single digits, particularly in industrial adhesives and electronics bonding solutions [18] - The U.S. market grew low single digits, driven by Electrical Markets and Personal Safety, but was partially offset by weakness in Auto OEM and Aftermarket [18] - Europe remained flat, with strength in Electrical Markets and Personal Safety, but weakness in Transportation Safety and Auto [18] Company Strategy and Development Direction - The company is focusing on innovation excellence, increasing the cadence of new product launches, with 64 new products launched in Q2, a 70% increase from last year [8][9] - A commitment to operational excellence is evident, with improvements in service, asset utilization, and quality metrics [12][14] - The company is tightening pricing controls and reducing customer churn through predictive analytics [11] Management's Comments on Operating Environment and Future Outlook - Management noted a sluggish global economy, with expectations for organic growth of approximately 2% for the year [16][25] - The company is navigating uncertain times by focusing on customer problem-solving through innovation and efficiency [17] - Management expressed confidence in meeting increased guidance and delivering strong shareholder returns in 2025 [27] Other Important Information - The company returned $3 billion to shareholders through dividends and share repurchases in the first half of the year [15] - A settlement with the State of New Jersey on PFAS claims was announced, with cash payments spread over 25 years [15][71] Q&A Session Summary Question: Can you talk about the new product plan and its impact on margin versus growth? - Management highlighted the importance of R&D and new product innovation, expecting both growth and margin improvements from new products [31][34] Question: What are the sources of operational upside in the footprint versus G&A? - Management indicated that productivity gains are split evenly between G&A and supply chain, with significant cost controls in place [42][44] Question: Can you elaborate on the tariff assumptions and mitigation actions? - Management updated the tariff impact to a gross headwind of $0.20, with mitigation through cost and sourcing changes [106][108] Question: How is the company managing PFAS liabilities? - Management confirmed ongoing discussions with state AGs and emphasized the importance of maintaining cash flexibility while addressing legacy issues [72][75] Question: What is the outlook for the consumer electronics market? - Management noted a softening demand in consumer electronics, with expectations for continued growth but at a slower rate [88]

Financial Data and Key Metrics Changes - The company reported adjusted earnings per share (EPS) of $2.16, a 12% increase year-on-year, exceeding expectations [5][19] - Organic sales growth was 1.5%, with all three business groups showing positive growth for the third consecutive quarter [5][16] - Operating margins increased by 290 basis points year-on-year, driven by productivity and cost controls [5][18] - Free cash flow was solid at $1.3 billion for the quarter, with a conversion rate of 110% [5][20] Business Line Data and Key Metrics Changes - Safety and Industrial organic sales grew by 2.6% in Q2, with six out of seven divisions posting positive results [21] - Transportation and Electronics adjusted sales were up 1% organically in Q2, led by commercial graphics and auto personalization [22] - Consumer business saw a slight increase of 0.3% organically in Q2, despite soft consumer sentiment [23] Market Data and Key Metrics Changes - Growth was led by China, which was up mid-single digits, driven by strong commercial execution [17] - The U.S. market grew low single digits, primarily in Electrical Markets and Personal Safety, but faced weakness in Auto OEM and Aftermarket [17] - Europe remained flat, with strength in Electrical Markets and Personal Safety, offset by weakness in Transportation Safety and Auto [17] Company Strategy and Development Direction - The company is focused on innovation excellence, increasing the cadence of new product launches, with 64 new products launched in Q2, a 70% increase from last year [6][7] - A commitment to operational excellence is evident, with improvements in service, asset utilization, and quality metrics [11][13] - The company is tightening pricing controls and reducing customer churn through predictive analytics [10] Management's Comments on Operating Environment and Future Outlook - Management noted a sluggish global economy, with expectations for organic growth of approximately 2% for the year [14][15] - The company is navigating uncertain times by focusing on customer problem-solving through innovation and efficiency [16] - Management expressed confidence in meeting increased guidance and delivering strong shareholder returns in 2025 [27] Other Important Information - The company returned $3 billion to shareholders through dividends and share repurchases in the first half of the year [14] - A settlement with the State of New Jersey on PFAS claims was announced, with cash payments spread over 25 years [14][70] - The company is exiting PFAS manufacturing by the end of the year, addressing legacy issues [72] Q&A Session Summary Question: Can you talk about the new product plan and its impact on margin versus growth? - Management highlighted the importance of R&D and new product innovation, expecting both growth and margin improvements as new products stabilize in the market [31][34] Question: What are the sources of operational upside in the footprint versus G&A? - Management indicated that productivity gains are split evenly between G&A and supply chain, with significant cost controls and procurement savings contributing to overall performance [44][46] Question: Can you elaborate on the tariff assumptions and their impact? - The company updated its tariff impact guidance, now estimating a gross headwind of $0.20, with mitigation actions in place to offset some of the costs [108] Question: How is the demand trend evolving, particularly regarding pre-buy concerns? - Management noted that while there may be some lingering pre-buy effects, overall orders were up low single digits, indicating stable demand trends [117]

Summary of Pfizer's Q1 2025 Earnings Call Company Overview - **Company**: Pfizer - **Date**: Q1 2025 Earnings Call Key Industry Insights - **Pharmaceutical Industry**: Pfizer is navigating a complex global landscape influenced by evolving trade and tariff policies, impacting operational strategies and financial performance. Core Strategic Priorities 1. **R&D Productivity**: - Focus on improving R&D productivity and advancing the pipeline with a disciplined approach to portfolio management [2][3][4] - Commitment to building a cardiometabolic pipeline, particularly in obesity, with potential partnerships or acquisitions [2][3] - New leadership in R&D with experienced professionals to enhance capabilities in oncology, vaccines, and inflammation immunology [3] 2. **Commercial Excellence**: - Separation of U.S. and international operations to enhance focus and strategic prioritization [6] - Strong performance in key products, with notable growth in the Vintakel family and Nurtec [6][7] - Continued emphasis on addressing unmet patient needs and improving access to treatments [7] 3. **Cost Management and Financial Performance**: - Q1 2025 revenues of $13.7 billion, a decline of 6% operationally, primarily due to lower Paxlovid revenues [8][9] - Adjusted diluted EPS of $0.92, benefiting from strong gross margin and cost management [8][9] - Ongoing productivity improvement programs expected to yield significant cost savings by 2027 [11] Financial Highlights - **Revenue**: $13.7 billion, down 6% operationally [8] - **Adjusted EPS**: $0.92, ahead of expectations [8] - **Gross Margin**: Expanded to approximately 81% [9] - **Operating Expenses**: Adjusted operating expenses decreased by 12% operationally [9] Pipeline and Product Development - Anticipated key milestones in 2025, including multiple regulatory decisions and phase three readouts [3][4] - Focus on innovative therapies for non-muscle-invasive bladder cancer and multiple myeloma [4] - Development of fourth and fifth generation PCV candidates to enhance vaccine offerings [5] Capital Allocation Strategy - Commitment to maintaining and growing dividends while investing in R&D and business development [10][22] - $2.4 billion returned to shareholders via dividends in Q1 [10] - Focus on improving cash flows and reducing debt leverage [10] Market Challenges and Responses - Impact of IRA Medicare Part D redesign and tariffs on U.S. revenues, with an estimated $650 million dampening effect in Q1 [8][30] - Ongoing assessment of tariff impacts, with potential costs anticipated to be around $150 million for 2025 [30] - Strategic focus on navigating macroeconomic uncertainties while maintaining operational efficiency [12][28] Future Outlook - Full year 2025 revenue guidance remains unchanged at $61 to $64 billion, with adjusted diluted EPS expected between $2.80 to $3.00 [12] - Continued emphasis on executing commercial strategies and enhancing shareholder value through disciplined cost management and innovation [13][22] Additional Considerations - The company is actively monitoring the evolving regulatory environment and potential impacts on operations and profitability [12][19] - Emphasis on leveraging digital capabilities and automation to drive operational efficiency and cost savings [11][22] This summary encapsulates the key points from Pfizer's Q1 2025 earnings call, highlighting the company's strategic priorities, financial performance, and outlook amidst a challenging market environment.

Financial Data and Key Metrics Changes - The company reported adjusted revenue growth of 4% in Q1 2025, exceeding expectations [7][16] - Adjusted EBITDA was $958 million, leading to an EBITDA margin of 37.8% [16][17] - Adjusted EPS grew 11% to $1.21, at the upper end of the outlook [8][17] - Free cash flow conversion exceeded 70%, with free cash flow of $368 million compared to $95 million last year [17][18] - The company returned $670 million to shareholders through share repurchases and dividends [8][19] Business Line Data and Key Metrics Changes - Banking segment revenue grew 2%, with recurring revenue growth at 3% [20][21] - Capital Markets segment saw adjusted revenue growth of 9%, with recurring revenue growth of 6% [21][22] - Non-recurring revenue in Capital Markets advanced 47%, driven by strong license renewals [21][22] Market Data and Key Metrics Changes - The company signed several new marquee engagements across various sectors, indicating strong demand for core solutions [8][9] - The digital solutions segment gained traction, with a Midwest community bank selecting the Digital One product [10] - The company expanded its relationship with a multinational engineering firm, enhancing its Office of the CFO capabilities [11] Company Strategy and Development Direction - The strategic acquisition of the Issuer Solutions business and the sale of the Worldpay stake are aimed at strengthening the company's financial profile and value proposition [6][14][15] - The company is focused on driving commercial excellence and simplifying its portfolio to deliver consistent financial results [6][7] - The acquisition is expected to be accretive to adjusted EPS and enhance recurring revenue streams [15][70] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the pipeline and noted no negative impacts from macro factors on client spending [32][33] - The company reaffirmed its full-year outlook, anticipating continued strength in recurring revenue growth [8][24] - Management highlighted strong visibility into cost reduction initiatives and margin improvement for the second half of the year [81][84] Other Important Information - The company is targeting adjusted revenue growth of 4.2% to 5% for Q2 2025, with banking revenue growth projected at 3.7% to 4.4% [24][26] - The company expects to achieve a total shareholder return of 11% to 13% for the year [26] Q&A Session Summary Question: Feedback on client decision-making pipeline and Issuer Solutions business - Management reported positive feedback on client conversions and an increasing pipeline, indicating strong demand for services [31][32] Question: Insights on Capital Markets Q2 guidance - Management noted that the first quarter had a high non-recurring benefit, and the second quarter guidance reflects a return to normalized levels [40][41] Question: Banking segment performance and drivers for acceleration - Management emphasized strong visibility into banking revenue growth driven by high retention rates and a strong sales year in 2024 [88][90] Question: Free cash flow and net working capital optimization - Management highlighted significant improvements in cash flow driven by net working capital initiatives and procurement strategies [97][98] Question: Potential dis-synergies from Worldpay sale - Management confirmed there are no dis-synergies from the Worldpay business as all impacts were accounted for during the separation [108] Question: ACV growth in Q1 - Management indicated strong growth in ACV across the business, consistent with historical trends [113][114]

Financial Data and Key Metrics Changes - The company reported adjusted revenue growth of 4% in Q1 2025, exceeding expectations [8][18] - Adjusted EBITDA was $958 million, leading to an EBITDA margin of 37.8% [18] - Adjusted EPS grew 11% to $1.21, at the upper end of the outlook [10][18] - Free cash flow conversion exceeded 70%, with free cash flow of $368 million compared to $95 million last year [9][19] - The company returned $670 million to shareholders through share repurchases and dividends [10][19] Business Line Data and Key Metrics Changes - Banking segment revenue grew 2%, with recurring revenue growth at 3% [21] - Capital Markets segment saw adjusted revenue growth of 9%, with recurring revenue growth of 6% [22] - Non-recurring revenue in Capital Markets advanced 47%, driven by strong license renewals [22] Market Data and Key Metrics Changes - The company signed several new marquee engagements across the money lifecycle, indicating strong demand for core solutions [10][11] - The digital solutions segment gained traction, with a Midwest community bank selecting the Digital One product [12] - The Office of the CFO capabilities expanded, with a multinational engineering firm selecting FIS's treasury management solution [13] Company Strategy and Development Direction - The company is focused on driving commercial excellence and simplifying its portfolio, which is expected to deliver consistent financial results [7] - The strategic acquisition of the Global Payments Issuer Business and the sale of the minority stake in Worldpay are aimed at strengthening the financial profile and value proposition [7][16] - The acquisition is expected to be accretive to adjusted EPS, EBITDA margins, and free cash flow in the first twelve months [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the pipeline, noting that client spending remains strong despite macroeconomic factors [32] - The company reaffirmed its full-year outlook, anticipating continued strength in recurring revenue growth [9][24] - Management highlighted the importance of high retention rates and strong sales from the previous year as drivers for future growth [90] Other Important Information - The company is targeting adjusted revenue growth of 4.2% to 5% for Q2 2025 [24] - Capital expenditures were $233 million in Q1 2025, consistent with full-year expectations [19] - The company exited the quarter at a target leverage of 2.8 times [19] Q&A Session Summary Question: Feedback on client decision-making pipeline and Issuer Solutions business - Management noted that client conversions are live and the pipeline is increasing significantly year-over-year, with no signs of slowing spend [31][32] Question: Outlook for Capital One and Discover - Management expressed positive sentiments regarding partnerships with Capital One and Discover, indicating strong support for their initiatives [36] Question: Drivers for Capital Markets Q2 guidance - Management explained that the first quarter had a high non-recurring benefit, and the second quarter guidance reflects a return to normalized levels [40][41] Question: Banking segment's combined debit issuing business - Management indicated that the banking segment will see a significant increase in scale and recurring revenue due to the acquisition [45][46] Question: Worldpay EMI outlook - Management confirmed that the Worldpay EMI outlook remains consistent with expectations, with no signs of softening [50][51] Question: Cost synergies from the acquisition - Management highlighted that the largest cost synergies would come from rationalizing duplicate vendor costs and back-office optimization [58][60] Question: Accretion from Issuer Solutions transaction - Management stated that the transaction is immediately accretive and will significantly enhance cash flow and banking revenue [69][70] Question: Free cash flow and working capital initiatives - Management reported significant improvements in cash flow due to net working capital optimization initiatives [98][99] Question: Sales progress in capital markets - Management noted strong opportunities in both traditional and non-traditional verticals, with a robust pipeline and execution [106]